Lentiviral RNA Splicing & Variants

Lentiviral RNA Splicing & Variants

Characterization of splicing and sequence variants in lentiviral vector (LVV) RNA: Built on high-depth Illumina strand-specific RNA-seq, this service localizes splice junctions (junction/PSI) and sequence variants (SNV/indel) at single-base resolution. It serves as orthogonal verification of conclusions from long-read direct RNA sequencing (Nanopore DRS), delivering traceable secondary confirmation that provides both "integrity" and "precision" lines of evidence for vector RNA.

1. Background

The sequence and splicing properties of lentiviral vector RNA directly determine whether the cassette of interest can be correctly transcribed and delivered. In vector design, cis-acting elements including the LTRs, Ψ, RRE, cPPT and WPRE jointly govern RNA splicing behavior and stability; once unintended splicing occurs (activation of cryptic splice sites, exon skipping) or low-frequency sequence variants arise, transgene expression, product homogeneity and safety characterization may be affected.

Sequencing technologies fall broadly into two categories, each with its own strengths. Long-read sequencing (Nanopore/PacBio) covers an entire molecule in a single read and excels at reconstructing full-length structure, splice/fusion junctions and complex regions, but its per-base random error rate is relatively high. Short-read sequencing (Illumina) fragments molecules and sequences them at high depth, delivering high per-base accuracy, large depth and stable quantification, yet cannot independently reconstruct long-range full-length structure. Picture a building: long reads provide a panoramic photograph, telling you whether the overall structure has misaligned or missing stories; short reads provide block-by-block high-resolution close-ups, telling you whether each individual brick is precisely in place. The two together yield conclusions that are both complete and precise.

When integrity conclusions will be incorporated into a regulatory submission package or used to inform critical process decisions, a "single method, single line of evidence" approach is often insufficient. Single-base resolution of splice sites and sensitive detection of low-frequency SNVs and small indels are particular strengths of high-depth short reads; using an independent, mechanistically different platform to cross-validate the splicing and deletion events identified by long reads substantially reduces the interpretation risk of any single method and aligns more closely with regulatory expectations for methodological rigor.

Regulatory and industry guidance for this service is clearly established: ICH Q5B (Analysis of the Expression Construct and Genetic Stability), Q6B (Specifications) and Q2(R2) (Validation of Analytical Procedures); FDA's "CMC Information for Human Gene Therapy INDs" (2020), which addresses purity and sequence characteristics within the vector CMC scope; and China NMPA/CDE's "Technical Guideline for Pharmaceutical Research and Evaluation of Ex Vivo Gene-Modified Systems (Trial)" (2022), which requires identification of CQAs, method validation and comparability. By providing an orthogonal methodological line of evidence, this service strengthens data credibility and provides supporting evidence for CQA interpretation.

Figure 1. Schematic of orthogonal verification across long-read and short-read sequencing platforms.

2. Technical Principle

This service is built on Illumina strand-specific RNA-seq, follows ENCODE data standards, and performs splice-site resolution and variant calling on lentiviral vector RNA at sufficiently high sequencing depth. Strand-specific library construction distinguishes between sense- and antisense-derived RNA, which is particularly important for interpreting vector transcriptional direction and splicing events; sufficient depth ensures that low-frequency splicing/variant events are stably detected and quantified; and the use of the same sample as — or a parallel aliquot to — the Lentiviral Vector RNA Integrity Analysis (DRS) enables item-by-item comparison of results. The core workflow is as follows:

(1) Sample receipt and QC

Receive vector RNA; assess concentration, purity, RIN value and preliminary integrity; confirm compliance with library construction requirements.

(2) Strand-specific RNA-seq library construction

Libraries are prepared according to standard strand-specific RNA-seq protocols; spike-in controls are introduced where necessary to assist quantitative calibration.

(3) High-depth Illumina sequencing

Sequencing is performed to the target depth; detection sensitivity for low-frequency splicing events and variants can be enhanced by increasing depth as required.

(4) Bioinformatic analysis and orthogonal cross-comparison

Alignment is performed against the customer-provided vector sequence as a custom reference; splice junctions are called, exon usage (Percent Spliced In, PSI) and coverage are computed, and SNVs and small indels are identified. Results are then cross-compared item by item against long-read (DRS) findings for consistency, and a cross-validation report is issued.

Figure 2. Workflow of the Lentiviral RNA Splicing and Variant Analysis service.

3. Technical Features and Advantages

(1) Single-base resolution interpretation

The Illumina platform offers industry-recognized high per-base accuracy, well suited to precise localization of splice sites and sensitive detection of low-frequency SNVs and indels, complementing the per-base random error of long-read sequencing.

(2) Orthogonal verification across two platforms

Conclusions are cross-validated item by item against long-read direct RNA sequencing (DRS), forming a complete "structure + precision" evidence chain. Consistent conclusions are robust and credible; points of discrepancy directly identify positions requiring re-examination.

(3) Strand-specific library construction enables transcript direction discrimination

Strand-specific RNA-seq distinguishes sense- vs. antisense-derived reads, supporting accurate interpretation of vector transcriptional direction and splicing behavior and avoiding the misinterpretation of complex vector transcription that can arise with conventional RNA-seq.

(4) Stable quantification and detection of low-frequency events

High-depth short reads ensure stable quantification of PSI and variant frequencies; detection sensitivity for low-frequency splice sites and heterogeneous variants scales with depth.

(5) Custom alignment to the client's vector

Read-by-read alignment is performed against the customer-provided full vector sequence as a custom reference, with cross-checking against public databases. Conclusions are quantitative, locus-resolved, and comparable across runs.

4. Applications

Orthogonal verification of integrity conclusions: Independent cross-validation of DRS long-read integrity findings to reinforce critical conclusions.

Precise localization of splicing events: Identify off-design splicing behavior such as cryptic splice-site activation and exon skipping.

Sensitive detection of low-frequency variants: Identify SNVs and small indels that are difficult to call reliably with long-read data.

Confirmation of vector engineering outcomes: Verify expected changes in splicing/variant profiles after sequence optimization or element redesign.

Strengthening of IND/BLA data packages: Provide dual-platform orthogonal evidence on vector RNA characteristics, enhancing methodological rigor.

5. Report and Deliverables

The report provides quantitative, locus-resolved, comparable sequence and splicing evidence. Core contents include:

·Splice junction catalog and PSI quantification: Per-locus listing of splicing events, exon usage and coverage.

·Sequence variant catalog: SNV and small-indel loci, types, frequencies and confidence levels.

·Coverage distribution and indicators of relative truncation/deletion.

·Cross-validation report against long-read DRS findings, with item-level annotation of agreements, discrepancies and items requiring re-examination.

·Verification of functional-element regions: Splicing and variant characteristics of LTRs, Ψ, RRE, cPPT, WPRE and other regions.

·Actionable recommendations: Re-examination strategies or downstream verification directions for any discrepancies.

·Data deliverables: Complete analysis report (PDF), variant/splice junction tables, alignment files and raw sequencing data.

6. Service Workflow

* Standard turnaround: 35–45 business days.

7. Sample Requirements

* The latest Sample Submission Guide takes precedence. This service is not applicable to severely degraded samples. Please schedule and confirm the study plan before sample submission.

8. Technical Specifications

9. References

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products. Current Step 4 version, 30 November 1995.

[2] ICH. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Current Step 4 version, 10 March 1999.

[3] ICH. Q2(R2): Validation of Analytical Procedures. Step 4 version, adopted 1 November 2023.

[4] U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER). Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry. Final, January 2020.

[5] Center for Drug Evaluation, National Medical Products Administration of China (NMPA-CDE). Technical Guideline for Pharmaceutical Research and Evaluation of Ex Vivo Gene-Modified Systems (Trial) [in Chinese]. Notice No. 31 of 2022, issued 26 May 2022.

[6] ENCODE Consortium. Standards, Guidelines and Best Practices for RNA-Seq. ENCODE Data Coordination Center.